-
Hunan Province Launches Pilot Program for Retail Sales of VBP Drugs with Strict Guidelines
•
The Hunan Healthcare Security Administration has released the “Pilot Implementation Plan for Volume-based Procurement (VBP) Drugs to Be Sold in Retail Pharmacies in Hunan Province,” outlining a strategic approach to integrating VBP drugs into the retail pharmacy landscape. The plan mandates the selection of at least one county (city) and…
-
China’s NMPA Suspends Dr. Reddy’s Atomoxetine Imports Amid Quality Concerns
•
BEIJING—The National Medical Products Administration (NMPA) has issued a notification to immediately suspend the import, sales, and use of Dr. Reddy’s Laboratories Ltd.’s atomoxetine hydrochloride capsules in China. The decision comes after the Indian pharmaceutical company’s product, which won a bid in the 9th round of China’s volume-based procurement (VBP),…
-
NHSA Mandates Standardized Online Procurement for Injectable Drugs to Ensure Pricing Transparency
•
The National Healthcare Security Administration (NHSA) has issued a directive to standardize the procurement process for injectable drugs, requiring that the smallest on-market preparation unit be used for online purchases. This move is aimed at achieving pricing transparency and reducing price disparities caused by variations in packaging quantities and conversion…
-
Shenzhen’s Draft Proposal for VBP Drug Procurement and Medical Insurance Fund Management Released
•
The Healthcare Security Administration (HSA) Bureau of the Shenzhen municipality has released a “Shenzhen Drug Volume-based Procurement (VBP) Medical Insurance Fund Balance Retention Management Measures (draft proposal)” and is soliciting public feedback until June 13, 2024. This document will apply to all VBP drugs with purchase agreements expiring this year…
-
NHSA Unveils 2024 Medical Procurement Overhaul, Aiming for Synergy Between National and Provincial Levels
•
The National Healthcare Security Administration (NHSA) has issued a notification detailing plans to enhance the medical centralized procurement process in 2024. The goals include strengthening local procurement alliances and achieving a coordinated procurement strategy between national and local levels. For the national volume-based procurement (VBP), new batches will be led…
-
China’s National Procurement Office Announces Continuous VBP for Joint Prosthetics
•
The National High-Value Medical Consumables Joint Procurement Office in China has initiated a new round of continuous volume-based procurement (VBP) for joint prosthetics. All provinces are mandated to participate in procurement alliances, including both public and private medical institutions. The Tianjin Pharmaceutical Procurement Center will handle the daily operations and…
-
China’s Health Authorities Investigate Alleged Price Manipulation in Pharma Procurement Tenders
•
Chinese health regulators are delving into allegations of irregular pricing practices during the national volume-based procurement (VBP) tenders for several pharmaceutical products. A joint statement issued by the National Drug Alliance Procurement Office and the Shanghai Pharmaceutical Centralized Bidding Procurement Management Office cited public complaints regarding the bidding and pricing…
-
Guangzhou and Zhuhai Unveil Measures to Stimulate Biopharmaceutical Industry Growth
•
In a bid to bolster the biopharmaceutical and health industries, the cities of Guangzhou and Zhuhai in Guangdong province have released Measures aimed at “Promoting High-Quality Development of the Biopharmaceutical Industry.” These policies are designed to refine the development environment and enhance the competitive edge of the sector. Guangzhou’s policy,…
-
NHSA Launches Service Specifications for Medical Procurement Platform
•
The National Healthcare Security Administration (NHSA) has issued the “Service Specification for Medical Centralized Procurement Platform (Version 1.0)”, which came into effect on July 1, 2024. This document, known as the “Regulations”, concentrates on service aspects of the centralized procurement platform, detailing procedures that include enterprise applications, information authentication standards,…
-
Shanghai Enhances Biomedicine IP Protection with New Procurement-Linked Measures
•
The Shanghai Intellectual Property Administration (SIPA) has issued a notification highlighting the city’s intensified efforts to protect intellectual property (IP) rights within the biomedicine industry. This strategic move comes on the heels of several high-profile administrative rulings on biopharmaceutical patent infringement disputes in Shanghai, underscoring a commitment to a linkage…
-
Fujian’s Fourth Round VBP Seeks Public Feedback on Drug Procurement List
•
The Fujian drug and device joint procurement center has published the “Fujian Fourth Round Drug Volume-Based Procurement (VBP) Document (draft proposal),” inviting public feedback until October 20, 2023. This initiative encompasses 50 chemical drugs and 24 Chinese patent drugs, with the procurement period set to last until December 31, 2025.…
